Pola-R-GemOx 对比 R-GemOx 治疗不适合移植的复发或难治性弥漫大B细胞淋巴瘤:III 期 POLARGO 随机试验结果
POLARGO 是一项随机、开放标签、全球性 III 期试验,纳入不适合自体干细胞移植的复发或难治性弥漫大B细胞淋巴瘤患者。共 255 例患者随机接受 Pola-R-GemOx 或 R-GemOx 治疗,主要终点为总生存期。
要点
- 中位 OS 分别为 19.5 个月 vs 12.5 个月,支持 Pola-R-GemOx 作为移植不耐受患者的治疗选择。
- 周围神经病变在 Pola-R-GemOx 组更常见(57% vs 29%),但主要为 1 级。
核心结论
- 在不符合自体干细胞移植条件的复发或难治性弥漫大B细胞淋巴瘤患者中,Pola-R-GemOx 相比 R-GemOx 显著改善总生存期。
研究设计与样本
- POLARGO 为 III 期、随机、开放标签、全球性研究,含 Pola-R-GemOx 安全性导入期(n=15),随后 1:1 随机分配至 Pola-R-GemOx 或 R-GemOx,每 21 天一次,最多 8 周期。
- 共 255 例患者随机分配:Pola-R-GemOx 组 n=129,R-GemOx 组 n=126。
- 纳入人群为复发或难治性弥漫大B细胞淋巴瘤(非特指型或转化性惰性淋巴瘤)且不适合自体干细胞移植的患者。
主要发现
- 中位总生存期:Pola-R-GemOx 组 19.5 个月(95%CI 13.3 至不可估计),R-GemOx 组 12.5 个月(95%CI 8.9-15.8)。
- 最常见的 3/4 级不良事件为血小板减少和中性粒细胞减少。
- 周围神经病变在 Pola-R-GemOx 组更常见(57% vs 29%),且主要为 1 级。
- 致死性不良事件在 Pola-R-GemOx 组和 R-GemOx 组分别发生 15 例(12%)和 5 例(4%),主要由感染(包括 COVID-19)所致。
关键数值与推荐
- 主要终点为总生存期。
- Pola-R-GemOx 组周围神经病变发生率为 57%(73 例),R-GemOx 组为 29%(36 例),主要为 1 级。
- 致死性不良事件发生率:Pola-R-GemOx 组 12%(15 例),R-GemOx 组 4%(5 例)。
临床怎么用
- 对于不适合自体干细胞移植的复发或难治性弥漫大B细胞淋巴瘤患者,Pola-R-GemOx 可作为新的治疗选择。
- 使用 Pola-R-GemOx 时需关注周围神经病变和感染风险,尤其是致死性感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) face an unfavorable prognosis once first-line treatment fails; therefore, there is an unmet need for new treatment options. We evaluated the efficacy and safety of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) as an alternative therapy in patients with transplant-ineligible R/R DLBCL. METHODS: The phase III POLARGO trial was a randomized, open-label, global study. Following a Pola-R-GemOx safety run-in (n = 15), patients with R/R DLBCL (not otherwise specified or transformed indolent lymphoma) ineligible for autologous stem cell transplant were randomly assigned 1:1 to receive Pola-R-GemOx or R-GemOx alone every 21 days for up to eight cycles. The primary end point was overall survival (OS). RESULTS: In total, 255 patients were randomly assigned to receive Pola-R-GemOx (n = 129) or R-GemOx (n = 126). After a median follow-up of 24.6 months, patients receiving Pola-R-GemOx versus R-GemOx had a significantly lower risk of death (hazard ratio, 0.6 [95% CI, 0.43 to 0.83]; P = .0017) with a median OS of 19.5 months (95% CI, 13.3 to not estimable) versus 12.5 months (95% CI, 8.9 to 15.8). The most common grade 3/4 adverse events (AEs) were thrombocytopenia and neutropenia. Peripheral neuropathy was more common with Pola-R-GemOx (n = 73 [57%]) versus R-GemOx (n = 36 [29%]) and was primarily grade 1. Fatal AEs occurred in 15 (12%) and five (4%) patients in the Pola-R-GemOx and R-GemOx groups, respectively, and were largely driven by infections (including COVID-19). CONCLUSION: Pola-R-GemOx significantly improved OS compared with R-GemOx, offering an additional treatment option in patients with transplant-ineligible R/R DLBCL.
引用
- Matasar M, Li Z, Vassilakopoulos TP, et al. Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial. J Clin Oncol. 2026. PMID: 42407012. doi:10.1200/JCO-25-02849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。